Biosimilars move to centre stage
This article was originally published in Scrip
Executive Summary
If anyone had any doubts that biosimilars are going to have a starring role in the future development of the pharmaceuticals industry they will have had them challenged by the sight of Pfizer signing a $200 million plus deal with India's Biocon and the fact that the FDA will be airing its thoughts on an approval pathway for such drugs at a public meeting on the 2nd and-3rd of November.